About Yongli Ji, MD, PhD

Dr. Ji earned her medical degree from Tianjin Medical University and pursued her Ph.D. in cancer biology at Brandeis University in Waltham, Massachusetts. Following that, she completed her residency at St. Vincent Hospital in Worcester, Massachusetts, and went on to a fellowship in the Hematology/Oncology division at the University of Vermont Medical Center in Burlington, Vermont. Dr. Ji has contributed to various publications and authored book chapters covering a wide range of topics, including breast cancer, lung cancer, meningioma, melanoma, ovarian cancer, and sarcoma. Notably, she has been an integral part of the board of directors for NNECOS (Northern New England Clinical Oncology Network) since 2021. Additionally, Dr. Ji dedicated nine years of service to the Institutional Review Board (IRB) at Exeter Hospital.

Clinical Interests:




Mass General Cancer Center in Danvers
102 Endicott St.
Danvers, MA 01923
Phone: 978-882-6060

Medical Education

  • PhD, Brandeis University
  • MD, Tianjin Medical University
  • Residency, St. Vincent Hospital @ Worcester Medical Center
  • Fellowship, University of Vermont Medical Center

American Board Certifications

  • Hematology, American Board of Internal Medicine
  • Internal Medicine, American Board of Internal Medicine
  • Medical Oncology, American Board of Internal Medicine

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


  • Select Publications:

    • Varkaris A , Fece de la Cruz F, Martin E, Norden B , Chevalier N , Kehlmann A, Leshchiner I, Barnes H , Ehnstrom S , Stavridi A , Yuan X , Kim J, Ellis H , Papatheodoridi A, Gunaydin H, Danysh B , Parida L , Sanidas L, Ji Y , Lau K, Wulf G, Bardia A, Spring L , Isakoff S, Lennerz J, Pierce L, Pazolli E, Getz G , Corcoran R, Juric D. Allosteric PI3K-alpha inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations. Cancer discovery (2023), 2023 Nov 2. doi: 10.1158/2159-8290.CD-23-0704.
    • Murphy N, Martinez-Lage M, Abramson J, Branagan A, Ji Y, Chen Y, Letourneau A, Nahed B, Nelson T, Arrillaga-Romany I, Wang N, Dietrich J, CNS Aspergillosis Following BTK Inhibitors Mimicking Secondary CNS Lymphoma ? A Case Series (P14-13.004). Neurology Apr 2023, 100 (17 Supplement 2) 3455; DOI: 10.1212/WNL.0000000000203281
    • Chowdhry V, Bushey J, Kwait R, Ritchie J, Goldberg S, Ji Y et al. Intraoperative radiation therapy as part of planned monotherapy for early-stage breast cancer. Journal of Radiation Oncology (2017).
    • Mori M, Ji Y et al. Phase II trial of subcutaneous methylnaltrexone in the treatment of severe opioid-induced constipation (OIC) in cancer patients: an exploratory study. Int J Clin Oncol (2016). doi:10.1007/s10147-016-1041-6
    • Ji Y, Tiffany R, Wood MW, et al. Atorvastatin versus placebo for reduction in biomarkers of breast cancer risk: a randomized phase II trial. Cancer Prev Res (Phila). 2016 May; 9(5): 379?384.
    • Ji Y, Grunberg SM, Verschraegen CF et al. Double Blind Randomized Trial of the Anti-Progestational Agent Mifepristone in the Treatment of Unresectable Meningioma, Phase III. J Clin Oncol. 2015 Dec 1;33(34):4093-8. Epub 2015 Nov 2.
    • Ji Y, Schwartz J et al. Successful treatment of non-small cell lung cancer with Erlotinib throughout the pregnancy. JAMA Oncology Sep 2015 Vol 1. No 6.
    • Othman E, Wang J, Sprague B, Round T, Ji Y, Wood MW et al. Comparison of False Positive Rates for Screening Breast MRI in High Risk Women performed in Stacked Versus Alternating Schedules. SpringerPlus 2015, 4:77
    • Monterroso J, Ji Y (Co-first Author), Emmons S, Verschraegen CF. Clinical approach to advanced melanoma for today and tomorrow (Book chapter, International Manual of Oncology Practice), 2014.
    • Rittiluechai K, Ji Y, Lounsbury K, Verschraegen CF. Clinical management of ovarian cancer (Book chapter, International Manual of Oncology Practice), 2014
    • Verschraegen CF, Movva S, Ji Y, Schmit B, Quinn QH, Liem B, Bocklage T, Monte S. A Phase I Study of the Combination of Temsirolimus with Irinotecan for Metastatic Sarcoma. A Phase I Study of the Combination of Temsirolimus with Irinotecan for Metastatic Sarcoma. Cancers 2013, 5 (2), 418-429. PMID: 24216984
    • He H, Fang P, Lv M, Ji Y. Study on the Expression of hTPO Epitopes Gene in E. coli BL21. TIANJIN MEDICAL JOURNAL. 2001, December 1.

Reviews: Comments and Ratings